The Regulatory Affairs Environment in Japan

Understand how to successfully navigate the Japanese health authorities and bring pharmaceutical products onto the Japanese market.

Register Download Material
  • 3. Nov 2020

3 days course

English

17.650,- DKK ex VAT
(app. 2.373,- EUR ex VAT)

Home > Courses & programmes > The Regulatory Affairs Environment in Japan

Module 4

Summary

This course will provide you with a thorough overview and in-depth case studies on how to successfully navigate the Japanese health authorities and bring pharmaceutical products onto the Japanese market. You will become familiar with the contents of drug dossiers, and the Japanese regulatory system, including the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labor and Welfare (MHLW). We will discuss the regulatory procedures throughout the drug development phases and how to successfully consult with PMDA, e.g., in the clinical trial notification phase.

You will get the latest trends in Japanese pharmaceutical regulations and procedures. You will receive lectures from senior Japanese regulatory professionals from industry, CROs and authorities.


Keywords

Japanese pharmaceutical regulation
Japanese regulatory authorities
PMDA
Orphan Drug Designation (ODD) in Japan
Clinical trial notification, clinical studies and Good Clinical Practice (GCP) in Japan
Japanese new drug application
Chemical pharmaceutical documentation requirements (CMC)
Non-clinical and clinical documentation and requirements
Regulations for biologics and biotechnology products
Generic drug regulation in Japan
Pharmacovigilance
National Health Insurance (NHI) pricing
Patent and regulatory data protection

What you will learn

  1. To understand the Japanese drug development and post-approval framework and regulatory procedure
  2. The do’s and don’ts of constructive interactions with Japanese colleagues and officials
  3. How to successfully navigate the PMDA consultations
  4. How to play an important role in any project team working on obtaining a marketing authorization in Japan

What your company will get

  1. An employee who understands the Japanese drug development, post-approval framework and regulatory procedures
  2. A regulatory professional who can make recommendations on how to achieve project goals in the shortest possible development time
  3. A regulatory professional who is able to successfully navigate the PMDA consultations
  4. A regulatory professional who can play an important strategic role in project teams working on obtaining a marketing authorization in Japan
Available start dates
All course dates: 3. Nov 2020, 4. Nov 2020, 5. Nov 2020
Download Material

Registration quick facts

You can pay by credit card or by invoice. We charge the amount shortly after you register. If you cancel your registration more than 30 days prior to the course, you will receive a full refund. Read our cancellation policy.

Yes, if you experience any technical problems, please call us at + 45 39 27 60 60, or send us an email at contact@atriumcph.com

If you cancel your registration more than 30 days prior to the course, you will receive a full refund. If you get sick and cannot attend the course, you may hand over the seat to a colleague, who will then have to register for the course on our website prior to course start. If the registration is closed, please send us full name, email, phone and title of your colleague to bfl@atriumcph.com. Read our cancellation policy.

Show allShow fewer Faqs

This course is a part of this programme

Regulatory Affairs Diploma

Theoretical and practical aspects ... Read more

WANT TO KNOW MORE ABOUT THIS COURSE?

Contact Client Manager Mette Ribergaard Rasmussen at +45 39 15 09 30

Send an email

 

You may also be interested in these courses